Search company, investor...

Pyxis Corporation


Acquired | Acquired

About Pyxis Corporation

Pyxis Corporation offers hospital medication management systems

Headquarters Location

3750 Torrey View Court

San Diego, California, 92130,

United States


Missing: Pyxis Corporation's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Pyxis Corporation's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Pyxis Corporation

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Pyxis Corporation is included in 1 Expert Collection, including Pharma Supply Chain.


Pharma Supply Chain

1,258 items

Pyxis Corporation Patents

Pyxis Corporation has filed 17 patents.

The 3 most popular patent topics include:

  • Semiconductor device fabrication
  • Electronics manufacturing
  • Packaging (microfabrication)
patents chart

Application Date

Grant Date


Related Topics




Packaging (microfabrication), Semiconductor technology, Electronics manufacturing, Wafer bonding, Semiconductor device fabrication


Application Date


Grant Date



Related Topics

Packaging (microfabrication), Semiconductor technology, Electronics manufacturing, Wafer bonding, Semiconductor device fabrication



Latest Pyxis Corporation News

Pyxis Tankers Inc. - Significant Improvement of Charter Rates Boosts Revenue Expectations

Jan 27, 2023

Highlights from the Pyxis Tankers session at the Capital Link Presentation Series include the following: Pyxis Tankers is an international pure play product tanker company engaged in seaborne transportation of refined petroleum products such as naphtha, gasoline, jet fuel, kerosene, diesel and fuel oil, as well as other liquid bulk items, such as vegetable oils and organic chemicals. Its fleet, which consists of 5 medium range product tankers (MR2s) with eco features, has a weighted average age of approximately 9.4 years and an aggregate carrying capacity of 249,554 dwt. Financial Highlights During the presentation, Henry Williams, CFO, mentioned that the Company had preliminary average fleet TCE of $33,400 per day in Q4 of 2022. As of January 16, 2023, 53% of available days in the first quarter of 2023 are booked at an average estimated TCE rate of $32,500 per day. “We have a very competitive total daily operational cost structure,” Eddie Valentis, CEO, stated. The Company’s total daily operational cash costs per Eco-efficient MR2 totaled $8,908 in in the third quarter ended September 30, 2022, compared to our larger U.S. listed peers which averaged of $9,654. Mr. Williams stated that in 2022, the Company experienced a “dramatic improvement in revenue” compared to the previous year. This increase in revenue was “driven by” an improvement of charter rates and the contribution from the acquisition of two MR’s. Pyxis’ EBITDA for the third quarter of 2022 was nearly $8 million. The Company’s near-term focus is “building further liquidity and strengthening its balance sheet,” stated the CFO. As of September 30, 2022, Pyxis’ net funded debt to total capitalization equaled 51.5%. Market Update - Sanctions on Russian Products & China’s Reopening to Bolster Market Generally, demand for refined petroleum products has increased in the past two years, due to post-pandemic global economic recovery as well as increased personal and commercial mobility. Impacts of the Russian-Ukrainian War and, more recently, China’s reopening have led to stronger chartering conditions for MR2s. Even though macro-economic conditions and geo-political events may create added volatility for the sector, demand for such vessels is expected to remain solid for the longer term. When asked if the upcoming price cap on Russian refined products will impact the product tanker sector, Mr. Valentis stated “this remains to be seen, but inventories are quite low for refined products in many locations…Overall, we expect that the market will improve in the coming months despite the recent unusually warm weather in the Northern Hemisphere and the temporary pull-forward of cargoes within Europe prior to the upcoming ban on Russian products.” Also, a significant portion of the refined products transported out of China, under new government approved quotas, will likely be “carried on MR vessels, especially to other Asian ports,” Mr. Valentis said. In terms of supply, Mr. Valentis noted that the MR2 orderbook is decreasing, with very little new ordering. Attractive vessel supply and demand fundamentals make for a strong market for MR2s. As Mr. Valentis pointed out, Russia provided a large quantity of refined products to Europe before the war in Ukraine; a fact which is changing after the sanctions levied on the country and the EU/G-7 ban effective February 5th. These regulations should force many countries to seek out alternative sources of refined products that should travel longer distances, which “will create an increase in ton-mile demand,” he stated. ESG Matters Pyxis’ fleet is about 2.5 years younger compared to the global industry fleet. All of its vessels have eco features, which provide for lower fuel consumption and emissions than standard tankers, and fully comply with environmental regulations. Rather than fitting its vessels with scrubbers, Pyxis runs its ships on compliant low-sulphur bunker fuel. It is more than a simple economic analysis. “We have taken the decision of not installing scrubbers…a scrubber investment in an MR vessel is not an easy installation,” and can create technical problems, Mr. Valentis stated. “Going forward, regarding alternative fuels, we haven’t seen substantial changes in our industry,” Mr. Valentis said when asked about the future of green fuels in the sector. What exactly the new, alternative fuel will be for middle-sized vessels “remains a question mark,” Mr. Valentis expressed. The debate surrounding alternative fuels and environmental technology tie into the Company’s strategy regarding newbuilds. “We will not order new vessels with existing technology. We would rather wait and see” regarding alternative fuels, the Pyxis CEO said. Rather, the preference remains the acquisition of secondhand modern eco vessels. Pyxis is focused on opportunistic fleet growth, particularly in terms of acquiring younger, eco-efficient IMO II & III MR2’s, which can “carry more types of cargoes to many ports worldwide,” Mr. Valentis stated. CAPITAL LINK- DISCLAIMER Capital Link is hosting a series of online Corporate Presentations, whereby the Senior Management teams of leading listed maritime companies present their business development, strategy, growth prospects, and overall sector outlook. The presentations are approximately 45 minutes and consist of a company presentation followed by live Q&A between company management and webinar participants. All presentations in the series can be accessed at . The webinars, including the ones mentioned above, are strictly for informational and educational purposes and should not be relied upon. They do not constitute an offer to buy or sell securities or investment advice or advice of any kind. The views expressed are not those of Capital Link which bears no responsibility for them. ABOUT CAPITAL LINK Founded in 1995, Capital Link provides Investor & Public Relations and Media services to several listed and private companies, including companies featured in the above mentioned webinars. Capital Link focuses mainly on the sectors of energy, commodities, maritime transportation, US Closed-End Funds and ETFs. Furthermore, Capital Link organizes a series of industry and investment conferences annually in key industry centers in the United States, Europe and Asia. Capital Link is a member of the Baltic Exchange. Based in New York City, Capital Link has presence in London, Athens & Oslo. For additional information, please visit: SUBSCRIBE TO CAPITAL LINK INSIGHTS Stay up to date on industry news and trends by subscribing to Capital Link Insights on LinkedIn at CONTACT

Pyxis Corporation Frequently Asked Questions (FAQ)

  • Where is Pyxis Corporation's headquarters?

    Pyxis Corporation's headquarters is located at 3750 Torrey View Court, San Diego.

  • What is Pyxis Corporation's latest funding round?

    Pyxis Corporation's latest funding round is Acquired.

  • Who are the investors of Pyxis Corporation?

    Investors of Pyxis Corporation include Cardinal Health, Menlo Ventures and Sprout Group.

  • Who are Pyxis Corporation's competitors?

    Competitors of Pyxis Corporation include OptiScan Biomedical, INRange Systems, Monica Healthcare, BioBehavioral Diagnostics Company, Apieron and 11 more.

Compare Pyxis Corporation to Competitors

INRange Systems

INRange Systems offers the EMMA system which manages outpatient medication delivery by selecting and delivering individual doses of medication for the patient in accordance with the physician's and pharmacist's instructions. The EMMA system aims to address the problem of noncompliance and drug errors has become an epidemic.


InformMed is a medication safety company developing, patenting and commercializing product and service-based solutions for the growing medication error solution market. InformMed is focused on providing nurses and pharmacists with performance support tools that aid in the level of safety for patients, caregivers and healthcare providers. InformMed's patented flagship product, pac2, is a hand-held performance-support system designed to help nurses prevent wrong dose errors at the point of care, a major healthcare concern.

Biowatch Medical

Biowatch Medical is the producer of "Sentry" a wearable vital signs monitor

E-Pill Logo

E-pill is a rapidly growing medical device manufacturer and distributor in the Boston area (Wellesley, Mass). Since 1999, e-pill, has focused on ways to monitor medication taking and help patients remember to take their medicines. They have been awarded the "Top Service" award by Yahoo! for customer service.They are dedicated to improving healthcare by developing practical patient compliance Medication Reminders and Age-In-Place medical devices.

Patton Medical Devices

Patton Medical Devices is a medical device company developing: I-Port Injection Port.The i-port® is a simple medication delivery device that relieves the hardships of daily injections for individuals with diabetes and other chronic conditions. Developed by KK Patton, a woman with diabetes, the i-port® aims to improve one's health and quality of life.

Exotic Technologies

After two years of development, testing and continuous improvement and trials at various hospitals, INFLO Infusion Flow Rate Monitor was introduced. INFLO is a microprocessor-controlled device with high level of accuracy, which can be used to monitor the infusion flow rate. Its low cost and low operating expenses as well as long life cycle aims to make it an alternative to the expensive infusion monitoring devices and aims to give accuracy and safety with inexpensive infusion sets.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.